论文部分内容阅读
Background Cilostazol is a kind of anti-platelet aggregation drugs with vasodilatory effects,which could inhibit the increasing of cAMP phosphodiesterase,so it could reduce intimal hyperplasia and reconstruction to anti-restenosis.As there lacks large sample trails to evaluate the efficacy and safety of triple antiplatelet therapy plus cilostazol compared to conventional dual antiplatelet therapy for patients after PCI,we collect the related trails to evaluate the efficacy and safety of triple antiplatelet therapy plus cilostazol compared to conventional dual antiplatelet therapy for patients after PCI.